NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Tim Noyes

Tim has 30 years’ industry experience leading all aspects of R&D and commercialization in the biopharmaceutical industry including Merck, Genzyme and Proteon. His extensive commercial planning and launch experience while at Genzyme, included leading the planning and commercialization of Renagel, a treatment for hemodialysis patients that resulted in Genzyme’s acquisition of GelTex for more than $1 billion.